Latozinemab  (Synonyms: AL001)

Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Sortilin/SORT1

Latozinemab (0.01-1000 nM, 48 h) reduces cell surface sortilin expression in U251 cells in a dose-dependent manner, with a maximum 63.8% decrease at 150 nM and an EC₅₀ of 0.105 nM^[1].
Latozinemab (0.01-1000 nM, 72 h) significantly increases extracellular PGRN levels in sortilin-expressing and PGRN-secreting human glioblastoma U-251 cells, with an EC₅₀ value of 0.68 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6272  [NCBI]

Q99523

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.28 kDa

2376132-27-1

Liquid

Colorless to light yellow

[Latozinemab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow cytometric analysis of 1X10⁶ K562 cells with Latozinemab (HY-P99688, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Kurnellas M, et al. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J Transl Med. 2023 Jun 15;21(1):387.  [Content Brief]

  [2]. Ek M, et al. An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation. Front Immunol. 2024 Aug 8;15:1437886.  [Content Brief]